North America Human Papillomavirus (HPV) Vaccine Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Human Papillomavirus (HPV) Vaccine Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Human Papillomavirus (HPV) Vaccine Market Regional Analysis

6.2 North America Human Papillomavirus (HPV) Vaccine Market Revenue 2020-2028 (US$ Million)

6.3 North America Human Papillomavirus (HPV) Vaccine Market Forecast Analysis

7. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Type

7.1 9-Valent HPV Vaccine

7.1.1 Overview
7.1.2 9-Valent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.2 Quadrivalent HPV Vaccine

7.2.1 Overview
7.2.2 Quadrivalent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.3 Bivalent HPV Vaccine

7.3.1 Overview
7.3.2 Bivalent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Dosage

8.1 2 Dose and 3 Dose

8.1.1 Overview
8.1.2 2 Dose and 3 Dose: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Age

9.1 9 to 14 Years and 15 to 45 Years

9.1.1 Overview
9.1.2 9 to 14 Years and 15 to 45 Years: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Application

10.1 HPV-Attributable Cancer and Genital Warts

10.1.1 Overview
10.1.2 HPV-Attributable Cancer and Genital Warts: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. North America Human Papillomavirus (HPV) Vaccine Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Key Country, 2023 and 2028 (%)
11.2.1.1 North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.1.1 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
11.2.1.1.2 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
11.2.1.1.3 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
11.2.1.1.4 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application

11.2.1.2 Canada: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.2.1 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
11.2.1.2.2 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
11.2.1.2.3 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
11.2.1.2.4 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application

11.2.1.3 Mexico : North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.3.1 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
11.2.1.3.2 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
11.2.1.3.3 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
11.2.1.3.4 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 ChengDu Institute of Biological Products Co., Ltd.

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Inovio Pharmaceuticals

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Merck & Co., Inc.

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 R-Pharm

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Sanofi

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Serum Institute of India Pvt. Ltd

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 Vaccitech

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Walvax Biotechnology Co., Ltd.

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America Human Papillomavirus (HPV) Vaccine Market